Table 3.
Patient | Date | IL-6 (pg/ml)a | CXCL9 (pg/ml)b | Disease activity |
---|---|---|---|---|
3a | 1/31/2012 | 3.80 | 2077 | Severe |
3b | 1/29/2013 | 4.50 | 1537 | Severe |
4a | 1/31/2012 | 13.90 | 1472 | Severe |
4b | 4/16/2013 | 19.30 | 8089 | Severe |
14a | 11/26/2012 | 1.80 | 300 | Severe |
14b | 12/11/2012 | 5.50 | 363 | Severe |
11a | 10/11/2012 | 0.24 | 317 | Mild |
11b | 11/15/2012 | 0.15 | 247 | Mild |
13a | 11/20/2012 | 0.88 | 282 | Mild |
13b | 12/11/2012 | 1.20 | 386 | Mild |
13c | 1/29/2013 | 1.20 | 703 | Mild |
IL-6 level > the 95th percentile of IL-6 among normal individuals (> 2.16 pg/ml) were considered positive (EIA assay).
CXCL9 level > the 95th percentile of CXCL9 among normal individuals (> 384 pg/ml) were considered positive (multiplex assay).